- Multi-product oncology deal for property which have validated targets and purpose to deal with efficacy and/or tolerability limitations of present therapies
- Consists of two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung most cancers (NSCLC), at the moment below US FDA evaluation for 2026 approvals
- Accelerates entry into lung most cancers, offering a platform for growth with Ris-Rez, GSK’s B7-H3 antibody-drug conjugate (ADC)
- Acquisition anticipated to be accretive to gross sales and core working revenue in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation
GSK plc (LSE/NYSE: GSK) at present introduced that it has entered an settlement to amass Nuvalent, Inc. (“Nuvalent”) (NASDAQ: NUVL) a Boston-based clinical-stage biopharmaceutical firm centered on creating exactly focused oncology therapies, for $10.6 billion. The acquisition is according to GSK’s technique of buying property which have validated targets and meaningfully tackle efficacy and/or tolerability limitations of present standard-of-care therapies. It consists of three merchandise in lung most cancers in a single transaction.
Zidesamtinib (NVL-520) and neladalkib (NVL-655) are two late-stage, potential best-in-class, next-generation, extremely selective ROS1 and ALK inhibitors for therapy of NSCLC. Each property have obtained FDA Breakthrough Remedy and Orphan Drug Designations* and are in evaluation with goal determination dates of 18 September 2026 for zidesamtinib and 27 November 2026 for neladalkib. Topic to FDA approval, they’re anticipated to launch in 2026 and have multi-blockbuster potential. The third asset, NVL-330, is a possible best-in-class HER2 inhibitor at the moment in section I trials for HER2-altered NSCLC. The acquisition additionally consists of Nuvalent’s preclinical portfolio of a number of programmes, constructed from their confirmed precision medication capabilities and scientific insights from industry-leading physician-scientists.
Luke Miels, Chief Govt Officer, GSK stated: “Right this moment’s acquisition is a multi-product deal, according to our method to amass property which have clinically confirmed targets and meaningfully tackle an efficacy and/or tolerability hole. The 2 lead merchandise are potential best-in-class property that would launch this yr if authorized by the FDA and provide important new therapy choices to sufferers with two types of non-small cell lung most cancers.
The acquisition supplies GSK with quick new gross sales progress alternatives, enhancing revenue contributions from 2027, and a platform in lung most cancers for speedy growth with Ris-Rez, our B7-H3 focused ADC in section III scientific improvement.”
Pivotal information introduced on the IASLC 2025 World Convention on Lung Most cancers and the 2026 ASCO Annual Assembly present potential best-in-class profiles for zidesamtinib and neladalkib.1,2 Each property purpose for longer efficient therapy with higher high quality of life by way of excessive target-selectivity, sturdy therapy response, improved tolerability, enhanced blood-brain barrier penetration for tumour unfold, and broader protection of ALK and ROS1 mutations, probably addressing efficacy and/or tolerability limitations of present therapies. ROS1- and ALK-altered NSCLC primarily have an effect on non-smoking adults aged 40-50, a uniquely outlined and engaged affected person inhabitants. There may be substantive therapy expertise with zidesamtinib and neladalkib already by way of their scientific improvement and affected person help programmes.3,4
James Porter, PhD, Chief Govt Officer, Nuvalent, stated: “Since our founding, we’ve got leveraged our deep experience in chemistry and structure-based drug design to develop a portfolio of novel, probably best-in-class kinase inhibitors. Our shut collaboration with main physician-scientists and affected person advocates has pushed exceptional enrolment, accelerating improvement and constructing confidence within the scientific profile of those medication. We’re excited that GSK has recognised the numerous worth these programmes can provide sufferers and shares our imaginative and prescient for practice-changing innovation. GSK’s confirmed monitor file, infrastructure, and experience will assist the profitable commercialisation of zidesamtinib and neladalkib, in addition to speed up development of our broader discovery pipeline.”
Monetary issues
Below the phrases of the merger settlement, GSK will start a young provide to amass all of Nuvalent’s excellent shares of Class A and Class B frequent inventory at a purchase order worth of $124 per share in money inside 10 enterprise days. The combination fairness worth of the transaction is estimated to be $10.6 billion (£8.0 billion). Web of money acquired, GSK’s mixture funding is estimated to be $9.4 billion (£7.1 billion). The anticipated buy worth of $124 per share represents a 40% premium to the final closing worth and a 26% premium to the 30 calendar day Quantity-Weighted Common Value (VWAP).
There isn’t a change to GSK’s 2026 full-year steering vary of 7-9% core working revenue and core EPS progress. The acquisition is predicted to contribute to income progress from 2027, be incremental to the Group’s present ambition for gross sales of >£40 billion by 2031 and to strengthen core working revenue by way of the dolutegravir lack of exclusivity interval (2028-2030). We count on accretion to core working revenue in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation. Assuming the transaction closes in Q3 2026, we count on low single-digit share dilution to core EPS for the present yr, FY 2027 and FY 2028.
The transaction will probably be funded primarily from new and present debt amenities plus money, with no impression anticipated to GSK’s credit standing. GSK will keep a robust funding grade credit score profile and retains steadiness sheet capability for additional accretive enterprise improvement.
GSK stays dedicated to its 70p anticipated dividend for 2026 and to its progressive dividend coverage thereafter.
The transaction is topic to customary closing situations, together with the tender of a majority of Nuvalent’s excellent shares of Class A typical inventory within the tender provide and the expiration or termination of the relevant ready interval below the Hart-Scott-Rodino Act within the US. Promptly following the closing of the tender provide, GSK expects to amass any remaining shares of Nuvalent by way of a second-step merger below Delaware regulation on the identical worth per share.
GSK will account for the transaction as a enterprise mixture. GSK can even assume Nuvalent’s present revenue-sharing preparations of low-single-digit royalties payable to Royalty Pharma and Deerfield.
Advisors
Leerink Companions LLC and Citigroup Inc. are performing as monetary advisors and Davis Polk & Wardwell LLP and Slaughter and Might are serving as authorized counsel to GSK in reference to the transaction. Centerview Companions LLC is serving as monetary advisor and Ropes & Grey LLP is serving as authorized counsel to Nuvalent. Jefferies LLC additionally supplied monetary recommendation to Nuvalent. Sidley Austin LLP is company counsel to Nuvalent.
About NSCLC
NSCLC is the commonest type of lung most cancers and is commonly characterised by particular genetic alterations, akin to these in ALK, ROS1, or HER2. It may possibly usually metastasise (i.e. unfold) to the central nervous system. It primarily impacts working-age people. Present therapies are related to mutation resistance and unintended effects, together with metabolic and neurologic occasions, that may adversely impression sufferers’ high quality of life.
Extra data
This press announcement is for informational functions solely and is neither a proposal to buy nor a solicitation of a proposal or a suggestion to promote securities, neither is it an alternative to the tender provide supplies that GSK plc, GlaxoSmithKline LLC (“GSK LLC”) and its wholly-owned subsidiary, Concord Row Acquisition Co. will file with the Securities and Trade Fee (the “SEC”). The tender provide for the excellent shares of Nuvalent Class A typical inventory and Class B frequent inventory described on this press announcement has not commenced. On the time the tender provide is commenced, GSK plc, GSK LLC and Concord Row Acquisition Co. will file, or will trigger to be filed, a Schedule TO Tender Provide Assertion with the SEC, and, thereafter, Nuvalent will file a Schedule 14D-9 Solicitation/Suggestion Assertion with the SEC, in every case with respect to the tender provide. The Schedule TO Tender Provide Assertion (together with a proposal to buy, a associated letter of transmittal and different provide paperwork) and the Schedule 14D-9 Solicitation/Suggestion Assertion will comprise necessary data that must be learn fastidiously earlier than any determination is made with respect to the tender provide. These supplies (as soon as they turn into accessible) will probably be made accessible to Nuvalent stockholders at no expense to them by the knowledge agent for the tender provide, which will probably be introduced. As well as, these supplies and all different paperwork filed by or brought on to be filed by Nuvalent or GSK plc with the SEC will probably be accessible at no cost on the SEC’s web site at www.sec.gov. Along with the Schedule 14D-9 Solicitation/Suggestion Assertion and Schedule TO Provide Assertion (as soon as every turns into accessible), Nuvalent and GSK plc file or furnish, as relevant, annual, quarterly and present reviews and different data with the SEC. Nuvalent and GSK plc filings with the SEC can be found to the general public from business document-retrieval providers and on the SEC’s web site at www.sec.gov.
About Nuvalent
Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical firm centered on creating exactly focused therapies for sufferers with most cancers, designed to beat the constraints of present therapies for clinically confirmed kinase targets. Leveraging deep experience in chemistry and structure-based drug design, Nuvalent develops progressive small molecules which have the potential to beat resistance, reduce opposed occasions, tackle mind metastases, and drive extra sturdy responses. Nuvalent is advancing a sturdy pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung most cancers, and a number of discovery-stage analysis packages.
About GSK
GSK is a world biopharma firm with a function to unite science, expertise, and expertise to get forward of illness collectively. Discover out extra at www.gsk.com.
Cautionary assertion concerning forward-looking statements
GSK plc cautions buyers that any forward-looking statements or projections made by GSK plc, together with these made on this announcement, are topic to dangers and uncertainties that will trigger precise outcomes to vary materially from these projected. Such components embrace, however are usually not restricted to, these described within the “Danger Elements” part in GSK plc’s Annual Report on Kind 20-F for the yr ended December 31, 2025, and GSK’s Q1 Outcomes for 2026. This communication consists of forward-looking statements associated to Nuvalent, neladalkib, zidesamtinib and the acquisition of Nuvalent by GSK plc which can be topic to dangers, uncertainties and different components. All statements aside from statements of historic reality are statements that may very well be deemed forward-looking statements, together with all statements concerning the intent, perception or present expectation of Nuvalent and members of its senior administration crew and might usually be recognized by phrases akin to “consider,” “count on,” “estimate,” “predict,” “goal,” “potential,” “probably,” “proceed,” “ongoing,” “might,” “ought to,” “intend,” “could,” “may,” “plan,” “search,” “anticipate,” “undertaking” and comparable expressions, in addition to variations or negatives of those phrases. Ahead-looking statements embrace, with out limitation, statements concerning the merger, comparable transactions, potential efficiency, future plans, occasions, expectations, efficiency, aims and alternatives and the outlook for Nuvalent’s enterprise; the flexibility of Nuvalent to efficiently commercialize its key merchandise, together with neladalkib and zidesamtinib; the anticipated timing of scientific information and regulatory filings or approvals regarding merchandise; the opportunity of favorable or unfavorable outcomes from scientific trials; the anticipated advantages of the acquisition; filings and approvals regarding the transaction; the anticipated timing of the completion of the transaction; the events’ capability to finish the transaction; and the accuracy of any assumptions underlying any of the foregoing. Traders are cautioned that any such forward-looking statements are usually not ensures of future efficiency and contain dangers and uncertainties and are cautioned to not place undue reliance on these forward-looking statements. Precise outcomes could differ materially from these at the moment anticipated resulting from a lot of dangers and uncertainties. Dangers and uncertainties that would trigger the precise outcomes to vary from expectations contemplated by forward-looking statements embrace: uncertainties as to the timing of the tender provide and completion of the merger; the likelihood that varied closing situations for the transaction will not be happy or waived, together with that Nuvalent stockholders could not tender into the provide a majority of the shares of Class A typical inventory excellent on the time of the expiration of the provide or that required regulatory approvals will not be obtained or are obtained topic to situations that aren’t anticipated; the prevalence of any occasion, change or different circumstance that would give rise to the termination of the merger settlement; the failure to comprehend anticipated advantages of the proposed acquisition when anticipated or in any respect; potential opposed reactions or adjustments to enterprise relationships ensuing from the proposed acquisition, together with the impact of the announcement, pendency or consummation of the acquisition on the flexibility of Nuvalent to retain and rent key personnel or keep key vendor, provider or accomplice relationships; dangers that the proposed acquisition disrupts the present plans and operations of Nuvalent; transaction prices; dangers related to potential litigation or regulatory actions associated to the transaction; and different dangers and uncertainties described every now and then in paperwork filed with the SEC by Nuvalent, together with present reviews on Kind 8-Ok, quarterly reviews on Kind 10-Q and annual reviews on Kind 10-Ok, in addition to the Schedule 14D-9 to be filed by Nuvalent, or in GSK plc’s Annual Report on Kind 20-F for the yr ended December 31, 2025 filed with the SEC by GSK plc, in addition to the Schedule TO to be filed by GSK plc. All forward-looking statements are based mostly on data at the moment accessible to GSK plc and Nuvalent, and neither GSK plc nor Nuvalent assumes any obligation to replace any forward-looking statements.
GSK makes use of variety of adjusted measures, together with Core outcomes, to report the efficiency of its enterprise, that are non-IFRS measures. These measures are outlined and reconciliations to the closest IFRS measure can be found in GSK’s Q1 2026 Outcomes and GSK’s Annual Report on Kind 20-F for FY 2025.
GSK supplies earnings steering to the investor group on the idea of Core outcomes. That is in keeping with peer firms and expectations of the investor group, supporting simpler comparability of the Group’s efficiency with its friends. GSK isn’t capable of give steering for Complete outcomes because it can not reliably forecast sure materials components of the Complete outcomes, notably the long run honest worth actions on contingent consideration and put choices that may and have given rise to important changes pushed by exterior components akin to foreign money and different actions in capital markets.
All expectations, steering and outlooks concerning future efficiency must be learn along with the part “Steerage and outlooks, assumptions and cautionary statements” on pages 44 and 45 of GSK’s Q1 2026 Outcomes and the statements on web page 328 of GSK’s Annual Report for FY 2025.
This announcement incorporates inside data. The particular person accountable for arranging the discharge of this announcement on behalf of GSK is Victoria Whyte, Firm Secretary.
* The FDA Breakthrough Remedy designation is designed to expedite the event and evaluation of medicines for critical situations, the place preliminary scientific proof signifies the potential for substantial enchancment over accessible remedy. Orphan Drug Designation is granted to assist the event and analysis of potential new medicines supposed for the therapy, prognosis or prevention of uncommon illnesses or issues.
References
- Drilon, A.E., et al. “Pivotal ARROS-1 Efficacy and Security Information: Zidesamtinib in TKI Pretreated Sufferers with Superior/Metastatic ROS1+ NSCLC”. IASLC 2025. Obtainable at: https://cdn.sanity.io/information/8miuua0t/manufacturing/49fc755646f2da35f684876f37076d73a9fff7c0.pdf. Final accessed: 8 June 2026.
- Lin, J.J., et al. “ALKOVE-1: Efficacy and security of neladalkib in sufferers with superior ALK+ NSCLC”. ASCO 2026. Obtainable at: https://cdn.sanity.io/information/8miuua0t/manufacturing/781d64797149fd79d2fdb9c732bd964560f3fd68.pdf. Final accessed: 8 June 2026.
- Nuvalent Pipeline. Obtainable at: https://nuvalent.com/pipeline. Final accessed: 7 June 2026.
- Nuvalent Expanded Entry Coverage. Obtainable at: https://nuvalent.com/expanded-access-policy. Final accessed: 7 June 2026.
